首页 > 最新文献

Ophthalmology最新文献

英文 中文
Association between Semaglutide and Non-Arteritic Anterior Ischemic Optic Neuropathy: A Multinational Population-Based Real-World Study. 塞马鲁肽与非动脉炎性前部缺血性视神经病变的关系:一项基于多国人群的真实世界研究。
IF 13.1 1区 医学 Q1 OPHTHALMOLOGY Pub Date : 2024-11-02 DOI: 10.1016/j.ophtha.2024.10.030
Chien-Chih Chou, Ssu-Yu Pan, Yi-Jing Sheen, Jun-Fu Lin, Chien-Heng Lin, Hui-Ju Lin, I-Jong Wang, Chien-Hsiang Weng

Objective: To investigate whether semaglutide increases the risk of non-arteritic anterior ischemic optic neuropathy (NAION) in the general population.

Design: This retrospective cohort study utilized a de-identified global electronic medical records database. The enrollment period was extended from January 2017 to August 2023, with observations concluding in August 2024.

Participants: This study included individuals with type 2 diabetes mellitus (T2DM) or obesity. They were further categorized into T2DM-only, obesity-only, and T2DM with obesity groups to assess the differences among these subgroups. The effects of semaglutide were compared with those of glucose-lowering or weight loss medications other than glucagon-like peptide receptor agonists.

Methods: Patient data were obtained from 160 healthcare organizations across 21 countries. Outcomes were evaluated at one, two, and three years of follow-up. A 1:1 propensity score matching was performed to balance age, sex, body mass index, hemoglobin A1C, medications, and underlying comorbidities. Cox regression models were used to compute hazard ratios (HR) and 95% confidence intervals (CI).

Main outcome measures: The occurrence of NAION.

Results: The final analysis included 37,245 participants with T2DM-only, 33,537 participants with obesity-only, and 64,989 participants with both T2DM and obesity. The results indicated that the administration of semaglutide was not associated with the development of NAION in the T2DM-only group (1 year follow-up: HR, 2.32; 95% CI, 0.60-8.97; 2 years: HR, 2.31; 95% CI, 0.86-6.17; 3 years: HR, 1.51; 95% CI, 0.71-3.25), the obesity-only group (1 year follow-up: HR, 0.25; 95% CI, 0.03-2.28; 2 years: HR, 0.44; 95% CI, 0.09-2.21; 3 years: HR, 0.44; 95% CI, 0.09-2.21), and the T2DM with obesity group (1 year follow-up: HR, 0.81; 95% CI, 0.42-1.57; 2 years: HR, 1.2; 95% CI, 0.74-1.94; 3 years: HR, 1.19; 95% CI, 0.78-1.82).

Conclusions: The findings suggest that semaglutide may not be associated with an increased risk of NAION in the general population. Therefore, avoidance of semaglutide based solely on concerns regarding the risk of NAION may not be warranted, as its potential benefits for blood glucose control and cardiovascular health likely outweigh its potential risks.

目的调查在普通人群中,塞马鲁肽是否会增加非动脉炎性前部缺血性视神经病变(NAION)的风险:这项回顾性队列研究利用了一个去标识化的全球电子病历数据库。入组时间从2017年1月延长至2023年8月,观察于2024年8月结束:研究对象包括 2 型糖尿病(T2DM)患者或肥胖症患者。他们被进一步分为纯 T2DM 组、纯肥胖组和 T2DM 伴肥胖组,以评估这些亚组之间的差异。将赛马鲁肽的疗效与胰高血糖素样肽受体激动剂以外的降糖或减肥药物的疗效进行比较:方法:从 21 个国家的 160 家医疗机构获取患者数据。对随访一年、两年和三年的结果进行了评估。在平衡年龄、性别、体重指数、血红蛋白 A1C、药物和基础合并症的基础上进行了 1:1 倾向评分匹配。采用考克斯回归模型计算危险比(HR)和 95% 置信区间(CI):结果:最终分析包括 37,245 名仅患有 T2DM 的参与者、33,537 名仅患有肥胖症的参与者以及 64,989 名同时患有 T2DM 和肥胖症的参与者。结果表明,在仅患有 T2DM 的组别中,服用塞马鲁肽与 NAION 的发生无关(随访 1 年:HR,2.32;95% CI,0.60-8.97;随访 2 年:HR,2.31;95% CI,0.60-8.97):HR,2.31;95% CI,0.86-6.17;3 年:HR,1.51;95% CI,0.71-3.25)、单纯肥胖组(1 年随访:HR,0.25;95% CI,0.03-2.28;2 年随访:HR,0.44;95% CI,0.60-8.97;2 年随访:HR,2.31;95% CI,0.86-6.17;3 年随访:HR,1.51;95% CI,0.71-3.25):HR,0.44;95% CI,0.09-2.21;3 年:HR,0.44;95% CI,0.09-2.21),以及 T2DM 伴肥胖组(随访 1 年:HR,0.81;95% CI,0.42-1.57;2 年:HR,1.2;95% CI,0.03-2.28):HR,1.2;95% CI,0.74-1.94;3 年:结论:结论:研究结果表明,在普通人群中,塞马鲁肽可能与NAION风险增加无关。因此,仅仅因为担心NAION的风险而避免服用塞马鲁肽可能是没有必要的,因为它对血糖控制和心血管健康的潜在益处可能超过其潜在风险。
{"title":"Association between Semaglutide and Non-Arteritic Anterior Ischemic Optic Neuropathy: A Multinational Population-Based Real-World Study.","authors":"Chien-Chih Chou, Ssu-Yu Pan, Yi-Jing Sheen, Jun-Fu Lin, Chien-Heng Lin, Hui-Ju Lin, I-Jong Wang, Chien-Hsiang Weng","doi":"10.1016/j.ophtha.2024.10.030","DOIUrl":"https://doi.org/10.1016/j.ophtha.2024.10.030","url":null,"abstract":"<p><strong>Objective: </strong>To investigate whether semaglutide increases the risk of non-arteritic anterior ischemic optic neuropathy (NAION) in the general population.</p><p><strong>Design: </strong>This retrospective cohort study utilized a de-identified global electronic medical records database. The enrollment period was extended from January 2017 to August 2023, with observations concluding in August 2024.</p><p><strong>Participants: </strong>This study included individuals with type 2 diabetes mellitus (T2DM) or obesity. They were further categorized into T2DM-only, obesity-only, and T2DM with obesity groups to assess the differences among these subgroups. The effects of semaglutide were compared with those of glucose-lowering or weight loss medications other than glucagon-like peptide receptor agonists.</p><p><strong>Methods: </strong>Patient data were obtained from 160 healthcare organizations across 21 countries. Outcomes were evaluated at one, two, and three years of follow-up. A 1:1 propensity score matching was performed to balance age, sex, body mass index, hemoglobin A1C, medications, and underlying comorbidities. Cox regression models were used to compute hazard ratios (HR) and 95% confidence intervals (CI).</p><p><strong>Main outcome measures: </strong>The occurrence of NAION.</p><p><strong>Results: </strong>The final analysis included 37,245 participants with T2DM-only, 33,537 participants with obesity-only, and 64,989 participants with both T2DM and obesity. The results indicated that the administration of semaglutide was not associated with the development of NAION in the T2DM-only group (1 year follow-up: HR, 2.32; 95% CI, 0.60-8.97; 2 years: HR, 2.31; 95% CI, 0.86-6.17; 3 years: HR, 1.51; 95% CI, 0.71-3.25), the obesity-only group (1 year follow-up: HR, 0.25; 95% CI, 0.03-2.28; 2 years: HR, 0.44; 95% CI, 0.09-2.21; 3 years: HR, 0.44; 95% CI, 0.09-2.21), and the T2DM with obesity group (1 year follow-up: HR, 0.81; 95% CI, 0.42-1.57; 2 years: HR, 1.2; 95% CI, 0.74-1.94; 3 years: HR, 1.19; 95% CI, 0.78-1.82).</p><p><strong>Conclusions: </strong>The findings suggest that semaglutide may not be associated with an increased risk of NAION in the general population. Therefore, avoidance of semaglutide based solely on concerns regarding the risk of NAION may not be warranted, as its potential benefits for blood glucose control and cardiovascular health likely outweigh its potential risks.</p>","PeriodicalId":19533,"journal":{"name":"Ophthalmology","volume":null,"pages":null},"PeriodicalIF":13.1,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142567920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Re: Israilevich et al.: Risk of endophthalmitis based on cumulative number of anti-VEGF intravitreal injections. (Ophthalmology 2024;131:667-673). Re:Israilevich 等人:基于抗 VEGF 玻璃体内注射累积次数的眼底病风险。(Ophthalmology 2024;131:667-673).
IF 13.1 1区 医学 Q1 OPHTHALMOLOGY Pub Date : 2024-11-01 DOI: 10.1016/j.ophtha.2024.09.027
Yohei Hashimoto
{"title":"Re: Israilevich et al.: Risk of endophthalmitis based on cumulative number of anti-VEGF intravitreal injections. (Ophthalmology 2024;131:667-673).","authors":"Yohei Hashimoto","doi":"10.1016/j.ophtha.2024.09.027","DOIUrl":"10.1016/j.ophtha.2024.09.027","url":null,"abstract":"","PeriodicalId":19533,"journal":{"name":"Ophthalmology","volume":null,"pages":null},"PeriodicalIF":13.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142583874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply. 答复
IF 13.1 1区 医学 Q1 OPHTHALMOLOGY Pub Date : 2024-11-01 DOI: 10.1016/j.ophtha.2024.09.028
Rachel N Israilevich, Jason Hsu
{"title":"Reply.","authors":"Rachel N Israilevich, Jason Hsu","doi":"10.1016/j.ophtha.2024.09.028","DOIUrl":"https://doi.org/10.1016/j.ophtha.2024.09.028","url":null,"abstract":"","PeriodicalId":19533,"journal":{"name":"Ophthalmology","volume":null,"pages":null},"PeriodicalIF":13.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142583877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dietary Supplementation for Retinitis Pigmentosa: A Report by the American Academy of Ophthalmology. 视网膜色素变性的膳食补充剂:美国眼科学会报告。
IF 13.1 1区 医学 Q1 OPHTHALMOLOGY Pub Date : 2024-10-23 DOI: 10.1016/j.ophtha.2024.09.004
Nieraj Jain, Maureen G Maguire, Christina J Flaxel, Stephen J Kim, Shriji Patel, Justine R Smith, Christina Y Weng, Leo A Kim, Steven Yeh

Purpose: To review the evidence on the effectiveness of dietary supplementation for retinitis pigmentosa (RP).

Methods: A literature search of the PubMed database was last conducted in January 2024 to identify published English-language original research on dietary supplementation for RP. Eligible compounds included products ingested orally containing nutrients intended to supplement the diet. Studies meeting eligibility criteria were assigned a level of evidence rating by the panel methodologist.

Results: The search identified 283 citations, 15 of which met the assessment criteria. Two studies were rated level I, 11 studies were rated level II, and 2 studies were rated level III. All were single-center studies and were published between 1993 and 2022. The products evaluated included vitamin A, docosahexaenoic acid (DHA), lutein, vitamin E, goji berry (Lycium barbarum fruit) extract, and chlorogenic acid. Primary outcome measures were most commonly based on electroretinography (n = 7) or perimetry (n = 2) testing. Numerous studies highlighted data suggestive of possible efficacy for vitamin A, DHA, and lutein, yet these findings typically derived from secondary outcomes, evaluations of participant subsets, post hoc analyses, problematic interpretations of the data, or a combination thereof. Additionally, it was often unclear if the study findings represented clinically meaningful outcomes. No prominent safety concerns were reported in any study.

Conclusions: No high-quality evidence was found to support the effectiveness of any form of dietary supplementation for RP. The findings underscore the challenges of studying this rare and slowly progressive retinal disease. Future studies should leverage the enhanced recruitment abilities from collaborative research networks to refine eligibility criteria while using novel, clinically meaningful endpoints.

Financial disclosure(s): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

目的:回顾膳食补充剂对视网膜色素变性(RP)有效性的证据:最后一次对PubMed数据库进行文献检索是在2024年1月,目的是确定已发表的有关视网膜色素变性膳食补充剂的英语原创研究。符合条件的化合物包括口服产品,其中含有旨在补充饮食的营养物质。符合资格标准的研究由专家组方法论专家进行证据等级评定:检索发现了 283 篇引文,其中 15 篇符合评估标准。2 项研究被评为 I 级,11 项研究被评为 II 级,2 项研究被评为 III 级。所有研究均为单中心研究,发表于 1993 年至 2022 年之间。接受评估的产品包括维生素 A、二十二碳六烯酸 (DHA)、叶黄素、维生素 E、枸杞子提取物和绿原酸。主要结果测量通常基于视网膜电图(7 项)或视周计(2 项)测试。许多研究强调了表明维生素 A、DHA 和叶黄素可能具有疗效的数据,但这些研究结果通常来自次要结果、对参与者子集的评估、事后分析、对数据的错误解释或上述因素的综合。此外,研究结果是否代表有临床意义的结果也往往不明确。所有研究均未报告突出的安全性问题:没有发现高质量的证据支持任何形式的膳食补充剂对 RP 有效。研究结果凸显了研究这种罕见且缓慢进展的视网膜疾病所面临的挑战。未来的研究应利用合作研究网络增强的招募能力来完善资格标准,同时采用新颖的、有临床意义的终点:专利或商业信息披露见本文末尾的 "脚注和披露"。
{"title":"Dietary Supplementation for Retinitis Pigmentosa: A Report by the American Academy of Ophthalmology.","authors":"Nieraj Jain, Maureen G Maguire, Christina J Flaxel, Stephen J Kim, Shriji Patel, Justine R Smith, Christina Y Weng, Leo A Kim, Steven Yeh","doi":"10.1016/j.ophtha.2024.09.004","DOIUrl":"https://doi.org/10.1016/j.ophtha.2024.09.004","url":null,"abstract":"<p><strong>Purpose: </strong>To review the evidence on the effectiveness of dietary supplementation for retinitis pigmentosa (RP).</p><p><strong>Methods: </strong>A literature search of the PubMed database was last conducted in January 2024 to identify published English-language original research on dietary supplementation for RP. Eligible compounds included products ingested orally containing nutrients intended to supplement the diet. Studies meeting eligibility criteria were assigned a level of evidence rating by the panel methodologist.</p><p><strong>Results: </strong>The search identified 283 citations, 15 of which met the assessment criteria. Two studies were rated level I, 11 studies were rated level II, and 2 studies were rated level III. All were single-center studies and were published between 1993 and 2022. The products evaluated included vitamin A, docosahexaenoic acid (DHA), lutein, vitamin E, goji berry (Lycium barbarum fruit) extract, and chlorogenic acid. Primary outcome measures were most commonly based on electroretinography (n = 7) or perimetry (n = 2) testing. Numerous studies highlighted data suggestive of possible efficacy for vitamin A, DHA, and lutein, yet these findings typically derived from secondary outcomes, evaluations of participant subsets, post hoc analyses, problematic interpretations of the data, or a combination thereof. Additionally, it was often unclear if the study findings represented clinically meaningful outcomes. No prominent safety concerns were reported in any study.</p><p><strong>Conclusions: </strong>No high-quality evidence was found to support the effectiveness of any form of dietary supplementation for RP. The findings underscore the challenges of studying this rare and slowly progressive retinal disease. Future studies should leverage the enhanced recruitment abilities from collaborative research networks to refine eligibility criteria while using novel, clinically meaningful endpoints.</p><p><strong>Financial disclosure(s): </strong>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</p>","PeriodicalId":19533,"journal":{"name":"Ophthalmology","volume":null,"pages":null},"PeriodicalIF":13.1,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142505260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Re: Singh: Transactional care and the looming glaucoma public health crisis (Ophthalmology 2024;131:877-879). Re:辛格:交易护理与迫在眉睫的青光眼公共卫生危机(《眼科学》2024;131:877-879)。
IF 13.1 1区 医学 Q1 OPHTHALMOLOGY Pub Date : 2024-10-22 DOI: 10.1016/j.ophtha.2024.09.023
Brice Dille
{"title":"Re: Singh: Transactional care and the looming glaucoma public health crisis (Ophthalmology 2024;131:877-879).","authors":"Brice Dille","doi":"10.1016/j.ophtha.2024.09.023","DOIUrl":"https://doi.org/10.1016/j.ophtha.2024.09.023","url":null,"abstract":"","PeriodicalId":19533,"journal":{"name":"Ophthalmology","volume":null,"pages":null},"PeriodicalIF":13.1,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142505263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Undiagnosed Von Willebrand Disease Detected after Dermal Filler. 皮肤填充术后发现未确诊的 Von Willebrand 病。
IF 13.1 1区 医学 Q1 OPHTHALMOLOGY Pub Date : 2024-10-22 DOI: 10.1016/j.ophtha.2024.09.022
Kendall Goodyear, Makayla McCoskey, Tanuj Nakra
{"title":"Undiagnosed Von Willebrand Disease Detected after Dermal Filler.","authors":"Kendall Goodyear, Makayla McCoskey, Tanuj Nakra","doi":"10.1016/j.ophtha.2024.09.022","DOIUrl":"https://doi.org/10.1016/j.ophtha.2024.09.022","url":null,"abstract":"","PeriodicalId":19533,"journal":{"name":"Ophthalmology","volume":null,"pages":null},"PeriodicalIF":13.1,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142505267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Double Crystalline Lens in a 3-Year-Old Child. 一名 3 岁儿童的双晶体眼。
IF 13.1 1区 医学 Q1 OPHTHALMOLOGY Pub Date : 2024-10-22 DOI: 10.1016/j.ophtha.2024.09.029
Muhammad Hanif, Muhammad Saad, Mujjaddad Rehman
{"title":"Double Crystalline Lens in a 3-Year-Old Child.","authors":"Muhammad Hanif, Muhammad Saad, Mujjaddad Rehman","doi":"10.1016/j.ophtha.2024.09.029","DOIUrl":"https://doi.org/10.1016/j.ophtha.2024.09.029","url":null,"abstract":"","PeriodicalId":19533,"journal":{"name":"Ophthalmology","volume":null,"pages":null},"PeriodicalIF":13.1,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142505261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply. 答复
IF 13.1 1区 医学 Q1 OPHTHALMOLOGY Pub Date : 2024-10-22 DOI: 10.1016/j.ophtha.2024.09.019
Taylor Potter, Louay Almidani, Pradeep Y Ramulu
{"title":"Reply.","authors":"Taylor Potter, Louay Almidani, Pradeep Y Ramulu","doi":"10.1016/j.ophtha.2024.09.019","DOIUrl":"https://doi.org/10.1016/j.ophtha.2024.09.019","url":null,"abstract":"","PeriodicalId":19533,"journal":{"name":"Ophthalmology","volume":null,"pages":null},"PeriodicalIF":13.1,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142505264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Re: Potter et al.: Concordance between self-reported visual difficulty and objective visual impairment: The National Health and Aging Trends Study (Ophthalmology. 2024 Jun 12:S0161-6420(24)00363-4.doi: 10.1016/j.ophtha.2024.06.009. Online ahead of print.). Re:波特等人自我报告的视觉困难与客观视觉损伤之间的一致性:国家健康与老龄化趋势研究》(Ophthalmology.2024 Jun 12:S0161-6420(24)00363-4.doi: 10.1016/j.ophtha.2024.06.009.Online ahead of print.)。
IF 13.1 1区 医学 Q1 OPHTHALMOLOGY Pub Date : 2024-10-22 DOI: 10.1016/j.ophtha.2024.09.018
Yating Zhou, Fei Xue
{"title":"Re: Potter et al.: Concordance between self-reported visual difficulty and objective visual impairment: The National Health and Aging Trends Study (Ophthalmology. 2024 Jun 12:S0161-6420(24)00363-4.doi: 10.1016/j.ophtha.2024.06.009. Online ahead of print.).","authors":"Yating Zhou, Fei Xue","doi":"10.1016/j.ophtha.2024.09.018","DOIUrl":"https://doi.org/10.1016/j.ophtha.2024.09.018","url":null,"abstract":"","PeriodicalId":19533,"journal":{"name":"Ophthalmology","volume":null,"pages":null},"PeriodicalIF":13.1,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142505262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply. 答复
IF 13.1 1区 医学 Q1 OPHTHALMOLOGY Pub Date : 2024-10-22 DOI: 10.1016/j.ophtha.2024.09.024
Kuldev Singh
{"title":"Reply.","authors":"Kuldev Singh","doi":"10.1016/j.ophtha.2024.09.024","DOIUrl":"https://doi.org/10.1016/j.ophtha.2024.09.024","url":null,"abstract":"","PeriodicalId":19533,"journal":{"name":"Ophthalmology","volume":null,"pages":null},"PeriodicalIF":13.1,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142505265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Ophthalmology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1